PharmGen Science Inc (004720) - Total Liabilities

Latest as of September 2025: ₩83.70 Billion KRW ≈ $56.72 Million USD

Based on the latest financial reports, PharmGen Science Inc (004720) has total liabilities worth ₩83.70 Billion KRW (≈ $56.72 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

PharmGen Science Inc - Total Liabilities Trend (2004–2024)

This chart illustrates how PharmGen Science Inc's total liabilities have evolved over time, based on quarterly financial data. See PharmGen Science Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

PharmGen Science Inc Competitors by Total Liabilities

The table below lists competitors of PharmGen Science Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Fractal Gaming Group AB ST:FRACTL	Sweden	Skr190.80 Million
Plastiques du Val de Loire PA:PVL	France	€538.89 Million
KMH Hitech Co. Ltd KQ:052900	Korea	₩79.08 Billion
QT Imaging Holdings, Inc. Common Stock NASDAQ:QTI	USA	$16.58 Million
TPXIMPACT HOLDINGS LS-01 F:9L7	Germany	€17.56 Million
Cheil Grinding KO:001560	Korea	₩12.41 Billion
T&R Biofab Co. Ltd KQ:246710	Korea	₩72.55 Billion

Liability Composition Analysis (2004–2024)

This chart breaks down PharmGen Science Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 004720 market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.25	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.34	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.25	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how PharmGen Science Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for PharmGen Science Inc (2004–2024)

The table below shows the annual total liabilities of PharmGen Science Inc from 2004 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩114.02 Billion ≈ $77.27 Million	+5.86%
2023-12-31	₩107.71 Billion ≈ $72.99 Million	-2.33%
2022-12-31	₩110.28 Billion ≈ $74.73 Million	+18.08%
2021-12-31	₩93.39 Billion ≈ $63.29 Million	+79.69%
2020-12-31	₩51.97 Billion ≈ $35.22 Million	+18.69%
2019-12-31	₩43.79 Billion ≈ $29.68 Million	+5.91%
2018-12-31	₩41.35 Billion ≈ $28.02 Million	+137.26%
2017-12-31	₩17.43 Billion ≈ $11.81 Million	-37.52%
2016-12-31	₩27.89 Billion ≈ $18.90 Million	+56.78%
2015-12-31	₩17.79 Billion ≈ $12.06 Million	-18.86%
2014-12-31	₩21.93 Billion ≈ $14.86 Million	+41.51%
2013-12-31	₩15.49 Billion ≈ $10.50 Million	-7.27%
2012-12-31	₩16.71 Billion ≈ $11.32 Million	-30.76%
2011-12-31	₩24.13 Billion ≈ $16.35 Million	-27.74%
2005-12-31	₩33.40 Billion ≈ $22.63 Million	+35.90%
2004-12-31	₩24.58 Billion ≈ $16.65 Million	+1.67%
2004-09-30	₩24.17 Billion ≈ $16.38 Million	--

About PharmGen Science Inc

KO:004720 Korea Drug Manufacturers - General

Market Cap

$44.55 Million

₩65.74 Billion KRW

Market Cap Rank

#22389 Global

#1407 in Korea

Share Price

₩3000.00

Change (1 day)

-4.46%

52-Week Range

₩3000.00 - ₩4925.00

All Time High

₩27300.00